Roquefort Therapeutics PLC Update on Acquisition of Oncogeni and Placing (8587P)

TIDMROQ

RNS Number : 8587P

Roquefort Therapeutics PLC

23 June 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Update on Acquisition of Oncogeni Limited and Placing

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that it has published a corporate presentation with respect to the proposed acquisition of Oncogeni Limited and the proposed Placing, as announced by the Company on 22 June 2022. A copy of the presentation is available on the Company's website at https://www.roquefortplc.com/category/presentations/

The Company looks forward to providing further updates in relation to the acquisition of Oncogeni Limited and the Placing as and when appropriate.

Enquiries:

 
  Roquefort Therapeutics plc 
                                           +44 (0)20 3290 
   Stephen West (Chairman)                           9339 
   Buchanan (Public Relations) 
    Ben Romney / Jamie Hooper / George 
    Beale 
                                           +44 (0)20 7466 
    Optiva Securities Limited (Broker)               5000 
                                           +44 (0)20 3411 
   Christian Dennis                                  1881

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQELLFLLQLZBBX

(END) Dow Jones Newswires

June 23, 2022 02:00 ET (06:00 GMT)

Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024